Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 2
2005 3
2006 1
2007 2
2008 2
2009 4
2010 1
2011 6
2012 4
2013 6
2014 9
2015 12
2016 2
2017 3
2018 4
2019 9
2020 12
2021 13
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction.
Smith EM, Benbahouche NEH, Morris K, Wilczynska A, Gillen S, Schmidt T, Meijer HA, Jukes-Jones R, Cain K, Jones C, Stoneley M, Waldron JA, Bell C, Fonseca BD, Blagden S, Willis AE, Bushell M. Smith EM, et al. Among authors: blagden s. Nucleic Acids Res. 2021 Jan 11;49(1):458-478. doi: 10.1093/nar/gkaa1189. Nucleic Acids Res. 2021. PMID: 33332560 Free PMC article.
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Bowtell DD, et al. Among authors: blagden s. Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Nat Rev Cancer. 2015. PMID: 26493647 Free PMC article. Review.
Controversies around the function of LARP1.
Berman AJ, Thoreen CC, Dedeic Z, Chettle J, Roux PP, Blagden SP. Berman AJ, et al. Among authors: blagden sp. RNA Biol. 2021 Feb;18(2):207-217. doi: 10.1080/15476286.2020.1733787. Epub 2020 Apr 1. RNA Biol. 2021. PMID: 32233986 Free PMC article. Review.
A decade of LARP society.
Blagden SP, Bayfield M, Bousquet-Antonelli C. Blagden SP, et al. RNA Biol. 2021 Feb;18(2):157-158. doi: 10.1080/15476286.2020.1755505. RNA Biol. 2021. PMID: 33651971 Free PMC article. No abstract available.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Among authors: blagden s. Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29. Lancet. 2019. PMID: 31791688 Free PMC article. Clinical Trial.
NICE public health guidance update.
Blagden S, Austin C, Richey R, Desai M. Blagden S, et al. J Public Health (Oxf). 2021 Apr 12;43(1):e107-e109. doi: 10.1093/pubmed/fdaa244. J Public Health (Oxf). 2021. PMID: 33423063
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Among authors: blagden s. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.
Blagden SP, Billingham L, Brown LC, Buckland SW, Cooper AM, Ellis S, Fisher W, Hughes H, Keatley DA, Maignen FM, Morozov A, Navaie W, Pearson S, Shaaban A, Wydenbach K, Kearns PR; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Br J Cancer. 2020 Feb;122(4):473-482. doi: 10.1038/s41416-019-0653-9. Epub 2020 Jan 6. Br J Cancer. 2020. PMID: 31907370 Free PMC article. Review.
83 results